Clinical Highlights

Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program

Dermatologic Surgery

• Author: Cohen, Joel L. et al.
• Published on February 8, 2021

Advanced Concepts in Rheology for the Evaluation of Hyaluronic Acid–Based Soft Tissue Fillers

Dermatologic Surgery

• Author: Faivre, Jimmy et al.
• Published on January 21, 2021

Learn More About Cervical Dystonia with Dr. Joseph Jankovic

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

Revance Announces Top-Line Results for ASPEN-1

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

Dermatologic Surgery

• Author: Green, Jeremy B. MD et al.
• Published on August 6, 2020

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

Dermatologic Surgery

• Author: Fabi, Sabrina G. MD et al.
• Published on August 6, 2020